Skip to main content
Premium Trial:

Request an Annual Quote

William Finger

Cancer Genetics has appointed William Finger as its executive VP of precision medicine and biopharma solutions. He will be responsible for developing and overseeing the company's precision medicine and biopharma and clinical trial business unit. Finger has more than 25 years of experience in the life sciences, diagnostics, and lab service industries. Before joining Cancer Genetics, he acted as managing director of precision medicine and diagnostics for Kineticos, a life science consultancy firm. Before Kineticos, Finger spent 12 years at Laboratory Corporation of America, where he held leadership positions in scientific affairs, preclinical services, biorepository, and operations.

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.